499 / 1109
FLAME trial
F
ocal
L
esion
A
blative
M
icroboost in prostat
E
cancer
Can dose escalation to the macroscopic tumor increase freedom from biochemical relapse rate?
Current five-year biochemical relapse rate: 35%
•
For patients with intermediate or high risk prostate cancer
PSA ≥ 10 ng/mL / Stage
≥
T2b / Gleason score
≥ 7
•
Endpoints:
Primary: 5-year freedom from biochemical relapse rate
Secondary: Toxicity, quality of life and disease-specific survival
Lips et al. Trials 2011